A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice

PHASE4CompletedINTERVENTIONAL
Enrollment

1,060

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

July 31, 2009

Conditions
Cardiovascular Disease
Interventions
DRUG

DEFINITY®

DEFINITY may be injected by either an intravenous or bolus injection or infusion. Dosage as per standard clinical practice and Package Insert

Trial Locations (16)

10025

St. Luke's-Roosevelt Hospital, New York

10029

Mt Sinai Medical Center, New York

15213

University of Pittsburgh, Pittsburgh

17405

York Hospital, York

19713

Alfieri Cardiology, Newark

27157

Wake Forest University Baptist Medical Center, Winston-Salem

55426

Park Nicolett Institute, Saint Louis Park

58122

Meritcare Heart Center Cardiology, Fargo

63110

St. Louis University, St Louis

64111

Cardiovascular Consultants, P.C., Kansas City

76104

Consultants in Cardiology, Fort Worth

77030

The Methodist DeBakey Heart Center, Houston

77555

University of Texas Medical Center, Galveston

92103-8411

UCSD Medical Center, San Diego

60611-2969

Northwestern University, Chicago

04210

Maine Research Associates, Auburn

Sponsors
All Listed Sponsors
lead

Lantheus Medical Imaging

INDUSTRY

NCT00625365 - A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice | Biotech Hunter | Biotech Hunter